ObjectiveThe world continues to face the COVID-19 crisis, and efforts are underway to integrate traditional medicine interventions for its effective management. The study aimed to determine the efficacy of the “AYURAKSHA” kit in terms of post-interventional percentage of COVID-19 IgG positivity, immunity levels, and quality of life (QoL) against COVID-19.MethodThis was a non-randomized controlled, prospective intervention trial, done after the distribution of 80,000 AYURAKSHA kits (constituent of Sanshamani Vati, AYUSH Kadha, and Anu Taila) among Delhi police participants in India. Among 47,827 participants, the trial group (n = 101) was evaluated with the positivity percentage of IgG COVID-19 and Immune Status Questionnaire (ISQ) scores as a primary outcome and the WHO Quality of Life Brief Version (QOL BREF) scores along with hematological parameters as a secondary outcome in comparison to the control group (n = 71).ResultsThe data showed that the percentage of COVID-19 IgG positivity was significantly lower in the trial group (17.5 %) as compared to the control group (39.4 %, p = 0.003), indicating the lower risk (55.6%) of COVID-19 infection in the trial group. The decreased incidence (5.05%) and reduced mortality percentage (0.44%) of COVID-19 among Delhi police officers during peak times of the pandemic also corroborate our findings. The ISQ score and WHO-QOL BREF tool analysis showed the improved scores in the trial group when compared with the controls. Furthermore, no dysregulated blood profile and no increase in inflammation markers like C-reactive protein, erythrocyte sedimentation rate, Interleukin-6 (IL-6) were observed in the trial group. However, significantly enhanced (p = 0.027) IL-6 levels and random blood sugar levels were found in the control group (p = 0.032), compared to a trial group (p = 0.165) post-intervention. Importantly, the control group showed more significant (p = 0.0001) decline in lymphocyte subsets CD3+ (% change = 21.04), CD4+ (% change = 20.34) and CD8+ (% change = 21.54) levels than in trial group, confirming more severity of COVID-19 infection in the control group.ConclusionThe AYURAKSHA kit is associated with reduced COVID-19 positivity and with a better quality of life among the trial group. Hence, the study encourages in-depth research and future integration of traditional medicines for the prevention of the COVID-19 pandemic.Clinical trial registrationhttp://ctri.nic.in/, identifier: CTRI/2020/05/025171.
Anaemia during pregnancy is a major public health problem throughout the world, particularly in the developing countries. According to WHO, prevalence of anaemia in pregnant women is estimated as 14 per cent in developed and 51 percent in developing countries. In India the prevalence is 65-75 percent. Acharya Kashyapa explained that like other disorders Samprapti of Pandu is also similar in Garbhini. So all narration mentioned in Ayurvedic classics regarding Pandu is applicable to Garbhini- Pandu. In the present study total 37 patients were recruited under the study and distributed into two groups Group-A (Draksha ghrita) and Group-B (Lakshmana lauha). After completion of trial 30 patients data was only available for assessment and 07 patients were dropped out from the study due to their irregular follow-up. On analysis of results, none of the patient has showed excellent relief. 10.00% and 30.00% patient has showed moderate relief in group A & B respectively. 06.00% and 10.00% patient in A and B group showed marked relief while 06.66% and 00.00% patient in has showed mild relief in A and B group and also the 26.66% and 16.66% patient has showed no relief. When the two groups A and B were compared with each other, the percentage of relief is found higher in group B, so it implies that group B is more clinically significant than group A. Overall conclusion of this study is that Draksha Gritha and Lakshmana lauha both drugs are effective, but Lakshmana lauha is comparatively better to cure the Subjective and Objective parameter of Garbhini Pandu.
Japakusumadi Yoga is an Ayurvedic formulation, indicated for contraception in Ayurveda. This study determines acute toxicity of ‘Japakusumadi Yoga’ an oral formulation in wister albino rats. Single dose acute toxicity was assessed by employing OECD guidelines 425 using AOT software. Test formulations was administered to overnight fasted animals and 14 days observation of dosed (up down as per requirement) rats was done for general appearance, cage side behaviour including increased or decreasing motor activity, convulsions, straub’s reaction, catatonia, muscle spasm, spasticity, ophisthotonus, hyperesthesia, muscle relaxation, anaesthesia, arching and rolling, lacrimation, salivation, diarrhoea, writhing movement, mode of respiration and changes in skin colour etc., with mortality and autopsy finding in case of dead animal. Based on the observation made and recorded it can be concluded that the test drug is without any toxic potential even at the dose of 2000 mg/kg in animals equivalent to 22.4g for human being.
Cervical erosion is the commonest causes of vaginal discharge in females, where ectocervix is covered by columnar epithelium, that means natural squamous epithelium is later replaced by columnar epithelium and appears like a Karnikakara granthi or Vrana depending upon the chronicity. The condition of cervical erosion is commonly treated in contemporary system of medicine with invasive therapies such as electric cauterization, cryosurgery etc. Kshara karma is a minimal invasive procedure that helps to destroy the ectopic columnar epithelium. So in the present study, a 40 year old woman diagnosed with cervical erosion (Karnini yonivyapad) was treated with Kshara karma using Apamarga Pratisarainiya kshara for 3 sittings each on alternate days for two cycles, starting from fifth day of the menstruation. After treatment significant reduction in the extent of cervical erosion was observed and the patient got relief in associated complaints. From this case study, it can be concluded that Kshara karma with Apamarga pratisaraniya kshara may be used as a safe and economical option for treating the cervical erosion.
Background: Yonidhoopana means the fumigation of vulva and vagina is the special local therapy men-tioned in Ayurveda classics in different yonivyapada, sukhprasava and sutika. It is an inseparable part of therapeutics in gynaecological disorders maintain sterilized external and internal environment of genitals. Various dhoopana drugs has been described in Bruhatrayi and Kashyapa Samhita that have Katu, Tikta, Laghu, Ruksha and Ushna properties on heating, get converted into volatile fumes cause dilatation and ox-idation of blood vessels and increase tissue perfusion. This antiseptic and sterilised environment of vagina is depicted by analgesic, anti-inflammatory and antimicrobial effect of Dhoopana. Various clinical research work related to yonidhoopana and antimicrobial effect of dhoopana has been conducted. Materials & Methods: Ayurvedic Samhita (Bruhtrayi), Kashyapa Samhita and literatures of striroga & prasuti tantra were studied out thoroughly. Original clinical research works, and review articles related to dhoopana were searched through online database search engine like Pubmed online, Researchgate, and Google scholar. Eight articles were selected and concluded. Discussion & Results: Yonidhoopana is very effective Sthani-ka chikitsa in yoniroga chikitsa, sukhprasava and sutikaparicharya due to its krimighna, kandughna, shothahara, vranaropaka, kledashoshaka effect in vulva and vagina. Hence, it is significantly proved in clinical research work of YONIDHOOPANA and antimicrobial dhoopana karma. Conclusion: Yonidhoopana has bacteriostatic action, economical, easy to perform and effective antimicrobial and anti-inflammatory procedure without any harmful effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.